Cost-effectiveness of Pola+R-CHP therapy for diffuse large B-cell lymphoma

Cost-effectiveness analysis of Polatuzumab vedotin+R-CHP combination therapy in Japan for previously untreated diffuse large B-cell lymphoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1031230035

Enrollment

879

Registered

2023-04-17

Start date

2023-04-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diffuse large B-cell lymphoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with previously untreated Diffuse large B-cell lymphoma

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Incremental cost-effectiveness ratio (ICER) for Pola+R-CHP compared to R-CHOP	—

Secondary

Measure	Time frame
1) Expected cost and effectiveness per patient in Pola + R-CHP therapy 2) Expected cost and effectiveness per patient in R-CHOP therapy	—

Contacts

Public ContactTakashi Mizuoka

Chugai Pharmaceutical Co., Ltd.

mizuokatks@chugai-pharm.co.jp+81-3-3273-0866

Outcome results